Jinhua unified the implementation of the new policy of serious illness insurance
Release time:
2020-08-14
Jinhua Unified Implementation of New Policy for Major Illness Insurance
Employees in need can choose to pay 1 to 3 copies
News From 2018 1 , the "Measures for the Implementation of Major Illness Insurance in Jinhua City" will be formally implemented. Compared with the original large medical insurance, this method further improves the level of medical protection. In addition to the basic payment at the unit, peak employees who need it can choose to pay 1 to 3 .
It is understood that the measures include the insured persons of the basic medical insurance for employees and the basic medical insurance for urban and rural residents into the scope of the implementation of serious illness insurance. By improving the financing mechanism of serious illness insurance, the level of serious illness insurance protection is improved, and the serious illness protection of the poor is established. Tilt mechanism to further reduce the burden of medical expenses for patients with serious illness. This time to establish and improve the serious illness insurance system, Jinhua City will implement the "six unifications", that is, unified policy system, unified financing standards, unified treatment level, unified undertaking agency, unified fund management, unified fund accounting, and unified income and expenditure of the serious illness insurance fund. At the same time, Jinhua City will promote the establishment of comprehensive service windows in designated medical institutions of medical insurance to realize "one-stop" information exchange and instant settlement such as basic medical insurance, critical illness insurance, and medical assistance.
serious illness insurance premium is composed of basic premium and optional premium, in which the basic premium is shared by the government, units and individuals in proportion and collected in combination with the basic medical insurance premium. According to the principle of "fixed income by expenditure, balance of income and expenditure, and slight surplus", a normal growth mechanism of basic premium financing for serious illness insurance is established, and the growth level is jointly determined by the Municipal Bureau of human resources and social security and the Municipal Bureau of finance. In addition to the basic premium, set up a major illness insurance optional premium program. The optional premium for each ,100 yuan is paid by individuals within the specified time, with a maximum of ,3 , which is linked to medical treatment and enjoys more if you pay more.
In order to further reduce the burden of large medical expenses on the poor, the new approach also establishes a precise relief mechanism for major illnesses, which makes it clear that major illness protection is tilted towards the poor. After the release of the measures for the implementation of serious illness insurance in Jinhua City, it has been highly concerned by the company. The basic payment of employees has been handled uniformly in the near future. Employees in need can go to the social security service window, commercial bank or mobile phone
for optional payment in addition to the basic payment. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page